FX06
- Generic Name
- FX06
- Drug Type
- Biotech
- Background
FX06 is a naturally occurring peptide derived from the neo-N-terminus of fibrin (Bbeta(15-42)). It prevents leukocyte migration through the gap junctions of endothelial cells. FX06 has proven safe in acute and subchronic toxicological studies and recently entered clinical development. It is being developed by Fibrex Medical Inc.
- Indication
Investigated for use/treatment in cardiac reperfusion injury and myocardial infarction.
FX06 to Rescue Acute Respiratory Distress Syndrome During Covid-19 Pneumonia
- First Posted Date
- 2020-11-05
- Last Posted Date
- 2021-06-22
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 50
- Registration Number
- NCT04618042
- Locations
- 🇫🇷
Service de Médecine Intensive Réanimation - CHI de Poissy, Chambourcy, France
🇫🇷Service de Médecine Intensive Réanimation - CHU Angers, Angers, France
🇫🇷Hôpital Pitié Salpêtrière, Paris, France
Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury
- Conditions
- Myocardial IschemiaCoronary DiseaseMyocardial Infarction
- Interventions
- Procedure: Percutaneous coronary intervention
- First Posted Date
- 2006-05-17
- Last Posted Date
- 2007-12-04
- Lead Sponsor
- Fibrex Medical Research & Development GmbH
- Target Recruit Count
- 234
- Registration Number
- NCT00326976
- Locations
- 🇦🇹
Wilhelminen-Spital, Vienna, Austria
🇧🇪Academisch Ziekenhuis van de vrije Universiteit, Brussels, Belgium
🇩🇪Universitätsklinikum Aachen, Aachen, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.